{"filing":{"accession_number":"0001628280-26-046340","cik":"0001357874","ticker":"DTIL","company_name":"PRECISION BIOSCIENCES INC","form":"8-K","filing_date":"2026-07-01","report_date":null,"primary_document":"dtil-20260701.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1357874/000162828026046340/dtil-20260701.htm"},"events":[{"id":15268,"run_id":13625,"accession_number":"0001628280-26-046340","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Precision Biosciences announced clinical trial progress for two gene-therapy programs: PBGENE-HBV demonstrated cccDNA elimination in the ELIMINATE-B study with a 1-log reduction in transcripts, and a second clinical site was activated at Washington University for the FUNCTION-DMD trial in Duchenne muscular dystrophy.","company_name":"PRECISION BIOSCIENCES INC","ticker":"DTIL","filing_date":"2026-07-01","form":"8-K","submitted_at":null,"items":[{"id":12964,"accession_number":"0001628280-26-046340","item_number":"8.01","item_title":"Other Events","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces clinical trial progress for two gene-therapy programs: PBGENE-HBV demonstrating cccDNA elimination in the ELIMINATE-B study with a 1-log reduction in transcripts, and activation of a second clinical site at Washington University for the FUNCTION-DMD trial in Duchenne muscular dystrophy. These represent material operational and clinical milestones for a biopharmaceutical company's pipeline development, though they do not fit the specific categories of earnings release, M\u0026A activity, or other defined event types.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T11:36:04.067674+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":15269,"run_id":13625,"accession_number":"0001628280-26-046340","anchor_item_number":"7.01","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.75,"summary":"The company furnished an updated corporate presentation deck to its investor relations website under Regulation FD Disclosure.","company_name":"PRECISION BIOSCIENCES INC","ticker":"DTIL","filing_date":"2026-07-01","form":"8-K","submitted_at":null,"items":[{"id":12963,"accession_number":"0001628280-26-046340","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.75,"reasoning":"This is a routine Regulation FD disclosure of an updated corporate deck posted to the investor relations website. The filing explicitly states the information is \"furnished\" under Item 7.01 and disclaims it as \"filed\" under Section 18 of the Exchange Act, indicating this is a non-material administrative disclosure. No substantive business, financial, or operational event is disclosed—only the availability of updated presentation materials.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T11:36:04.067674+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":12963,"accession_number":"0001628280-26-046340","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.75,"reasoning":"This is a routine Regulation FD disclosure of an updated corporate deck posted to the investor relations website. The filing explicitly states the information is \"furnished\" under Item 7.01 and disclaims it as \"filed\" under Section 18 of the Exchange Act, indicating this is a non-material administrative disclosure. No substantive business, financial, or operational event is disclosed—only the availability of updated presentation materials.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T11:36:04.067674+00:00","company_name":"PRECISION BIOSCIENCES INC","ticker":"DTIL","filing_date":"2026-07-01"},{"id":12964,"accession_number":"0001628280-26-046340","item_number":"8.01","item_title":"Other Events","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces clinical trial progress for two gene-therapy programs: PBGENE-HBV demonstrating cccDNA elimination in the ELIMINATE-B study with a 1-log reduction in transcripts, and activation of a second clinical site at Washington University for the FUNCTION-DMD trial in Duchenne muscular dystrophy. These represent material operational and clinical milestones for a biopharmaceutical company's pipeline development, though they do not fit the specific categories of earnings release, M\u0026A activity, or other defined event types.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T11:36:04.067674+00:00","company_name":"PRECISION BIOSCIENCES INC","ticker":"DTIL","filing_date":"2026-07-01"}]}